Organ Preservation Market by Solution (UW/Custodiol HTK/Perfadex), Technique (Static Cold Storage/Hypothermic Machine Perfusion/ Normothermic Machine Perfusion), Organ Type (Kidneys/Liver/Lungs/Heart), Region – Global Forecast to 2024

2020-02-10
Price :
Published : Feb-2020
No. of Pages : 140

“The organ preservation market is projected to grow at a CAGR of 6.5%.”

The global organ preservation market is projected to reach USD 284 million by 2024 from USD 207 million in 2019, at a CAGR of 6.5%. The growth of the organ preservation market is mainly driven by the increasing incidence of multi-organ failure, the growing geriatric population, the rising number of organ transplants and organ donors, and increasing initiatives to encourage organ donations. However, the high cost of organ transplantations and religious concerns in specific geographies are expected to limit market growth to a certain extent.

“The University of Wisconsin (UW) holds the market share in the solutions market.”

Based on the Solution, the segment is divided into UW, Custodial HTK, Perfadex and Other solutions (EuroCollins and Celsior). In 2019, the UW solution accounted for the highest share of 92.92 USD million in 2019. The UW solution is used for the flushing and storage of kidneys, liver, and pancreas. It was the first intracellular preservation medium, considered the gold standard for organ preservation. Paradox accounts for themost considerable CAGR in the forecast period of 2019-2024.

“Normothermic Machine Perfusion accounts for the highest CAGR in the forecast period.”

Normothermic machine perfusion marked the highest CAGRin the forecast period of 2019 to 2024. Normothermic perfusion is a technique that recreates the physiologic environment by maintaining average organ temperature and providing essential substrates for cellular metabolism, oxygenation, and nutrition. It is said to enhance the safety and efficacy of the organ and improve repair before transplantation. The normothermic technique is said to reduce the pro-inflammatory response in the liver and the risk of ischemic injuries while promoting graft regeneration. The possibility of long-term graft survival and reduced delayed graft functioning in organs of marginal quality (such as those from older donors) has made normothermic machine perfusion increasingly relevant.

Static cold storage and hypothermic machine perfusion are the other techniques involved in this segment.

“Kidneys holds the highest share in the segment by organ type.”

Kidneys accounts for a market share in the organ segment. Renal transplantation is considered the treatment of choice for patients with end-stage renal disease (ESRD) or kidney failure, diabetes,etc.are all cause for the growth of this segment. Other causes of ESRD in adult patients are polycystic kidney disease and glomerulonephritis. With the rising incidence of diabetes, the number of patients with ESRD or kidney failure is expected to increase, which will drive demand for kidney transplants. Moreover, improvements in graft survival and long-term graft function have made kidney transplantation a cost-effective alternative to dialysis. Major organs like Lungs, Liver, Kidney and Heart are a part of this segment.

“The Asia Pacific to witness the highest growth during the forecast period.”

Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2019–2024. The major factors driving the growth of the Asia Pacific market include favorable government initiatives, increased awareness in people and increased organ donations. Intensified public education, mobilization, and advancements in organ transplant technologies have improved the donation rate in China. In India, Rapid improvements in the country’s healthcare infrastructure have supported market growth while encouraging medical tourism. The willingness to donate organs in Japan has led to the improvement in organ donation despite religious issues. Other countries have initiative reimbursement programs, paired organ donation scheme with other patients within the country and across countries, have improved the growth of this market drastically.

Break of primary participants was as mentioned below:

  • By Company Type: Tier I: 50%, Tier II: 30%, Tier III: 20%
  • By Designation: C-Level Executives: 37%, Directors: 29%, Others: 34%
  • By Region: North America: 35%, Europe: 30%, Asia Pacific: 25%, RoW: 10%

XVIVO Perfusion AB (Sweden), Paragonix Technologies (US), Dr. Franz Kohler Chemie GMBH (Germany) are the leading players in the organ preservation market.

Research Coverage

This report studies the organ preservation market based on solution, technique, organ type, and region. The report also studies the different factors (such as drivers, restraints, and opportunities) affecting the market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets concerning their growth trends and forecasts the revenue of the market segments with respect to four central regions and respective countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the organ preservation market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the organ preservation market.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : marketsandmarkets
More Reports
Title Price Buy Now

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) – Global Forecast to 2025

 “Growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD) is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Growth in the plasma fractionation market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-ant......
$4950

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (Practice Management, e-Prescribing, PHM, Health Analytics, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User – Global Forecast to 2025

“Government support to increase adoption of EHR solutions is expected to drive the overall growth of the ambulatory EHR market.” The ambulatory EHR market is expected to reach USD 6.8 billion by 2025 from USD 5.2 billion in 2020, at a CAGR of 5.7% during the forecast period of 2020 to 2025. Growth in the global ambulatory EHR market can primarily be attributed to various factors such as government support for the adoption of EHR solutions, increasing number of outpatient care centers, growing patient volume due to the global outbreak of COVID-19, and the need to curtail healthcare costs. On the other hand, market growth is limited to a certain extent due to factors such as reluctance to adopt EHR solutions in developing countries, heavy infrastructure investments, and the high cost ......
$4950

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020" provides an overview of Functional (Non Ulcer) Dyspepsia Clinical trials scenario. This report provides top line data relating to the clinical trials on Functional (Non Ulcer) Dyspepsia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDa......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinica......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H2, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – July 2020

Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals - July 2020 Summary GlobalData's "Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals - July 2020" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Addit......
$1000

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020" provides an overview of Neisseria meningitidis Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Neisseria meningitidis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using Glob......
$2500

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Oropharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Oropharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical tr......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy